The Upside Down: Delphia Therapeutics Launches to Treat Cancer with Activation Lethality
Kevin Marks, PhD, has been involved in successful endeavors to create meaningful medicines over his 20-year career as a cancer drug hunter, including spells as the head of oncology drug discovery at Novartis Institutes for BioMedical Research (NIBR) and …